Pre-Open Movers 06/30: (CARV) (BYFC) (BLNK) Higher; (OCX) (ZYNE) (GNW) Lower (more...)

Acuity Brands (AYI) PT Raised to $122 at Cowen Following 3Q

Cowen analyst Jeffrey Osborne raised the price target on Acuity Brands (NYSE: AYI) to $122.00 (from $115.00) while maintaining a Outperform rating following the company's 3Q earnings report. Revenue of $776.2mn was above the consensus of $741.6mn. Adjusted EPS came in at $1.94 vs. the Street's forecast of... More

Acuity Brands (AYI) PT Raised to $96 at Baird Following 3Q Beat

Baird analyst Timothy Wojs raised the price target on Acuity Brands (NYSE: AYI) to $96.00 (from $95.00) while maintaining a Neutral rating following the company's 3Q earnings report. AYI reported EPS of $1.94 compared with the consensus estimate of $1.22. Revenue was $776m, coming in ahead of the... More

UPDATE: Needham & Company Downgrades Zynerba Pharmaceuticals (ZYNE) to Hold

(Updated - July 1, 2020 7:22 AM EDT)

(updating comment)

Needham & Company analyst Serge Belanger downgraded Zynerba Pharmaceuticals (NASDAQ: ZYNE) from Buy to Hold.

The analyst comments "Zygel missed primary and secondary endpoints in the pivotal ph 3 CONNECT-FX trial, but met the... More

CRISPR Therapeutics (CRSP) Prices 6.428M Share Common Offering at $70/Sh

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 6,428,572 common shares at a public offering price of $70.00 per share. In addition, the underwriters have a 30-day... More

Acceleron Pharma (XLRN) Prices 4.864M Share Common Offering at $92.50/Sh

Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that it has priced an underwritten public offering of 4,864,864 shares of common stock at a price to the public of $92.50 per share for gross proceeds of $450.0 million. In connection with this offering, Acceleron has granted the... More